Awareness and Equity in OC

CE / CME

Improving Provider Awareness About Healthcare Equity: Improving All Patients’ Access to Care in Ovarian Cancer

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: April 25, 2023

Expiration: April 24, 2024

Shannon N. Westin
Shannon N. Westin, MD, MPH, FASCO

Activity

Progress
1
Course Completed

Equity in Ovarian Cancer

Despite exciting advances in the field of gynecology oncology, underrepresented patients of color disproportionally face barriers to optimal/equitable care for ovarian cancer. Moreover, data also suggest that many providers caring for patients with ovarian cancer are unaware of the disparities in their field. Recognition and raising awareness of factors contributing to inequities is an important first step in improving care for all women with ovarian cancer to help overcome these barriers to care. 

In this module, Shannon N. Westin, MD, MPH, reviews and discusses key factors leading to inequitable care for ovarian cancer and proposes strategies to overcome them with guideline-concordant care. This module is part of  a larger educational program tasked with raising awareness and sharing expert’s strategies for improving outcomes for all women with gynecologic cancer. 

Please note that the slide thumbnails in this activity link to PowerPoint slidesets that also can be found here, each focused on the specific gynecologic topic of interest. These slidesets also may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: Once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a healthcare professional providing patient care, how many patients with ovarian cancer do you see in a typical month?

Based on current approved indications, which of the following PARP inhibitors would be appropriate to consider for patients with BRCA-mutant, recurrent, high-grade serous ovarian cancer who have received 2 previous chemotherapy regimens?